BRTX
BioRestorative Therapies, Inc.
There isn't enough reported data to score BRTX yet.
BRTX Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Weak | |
| Unavailable |
BRTX's revenue, profitability and cash flow are currently weak. There isn't enough data to rate its balance sheet.
BRTX PE Valuation
BRTX has no meaningful PE right now: it lost money over the past year.
BRTX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| -- |
Analysts expect BRTX's losses to shrink, with revenue growing.
BRTX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q1 2026 | -$21.20 | +$8.20 |
| Q4 2025 | -$31.60 | -$8.40 |
| Q3 2023 | -$82.67 | +$641.93 |
| Q2 2023 | -$95.47 | +$703.33 |
| Q1 2023 | -$105.67 | +$667.53 |
| Q4 2022 | -$102.47 | +$1,443.33 |
| Q3 2022 | -$724.60 | +$175.20 |
| Q2 2022 | -$798.80 | +$1.20 |
BRTX is still losing money, but far less than before: $21.20 per share over the past year, against $1,545.80 at its worst in late 2021.
BRTX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q4 2025 | $34.6K | -71% |
| Q3 2025 | $57.7K | -75% |
| Q2 2025 | $303.3K | +72% |
| Q1 2025 | $100K | -39% |
| Q4 2024 | $119K | -68% |
| Q3 2024 | $233.6K | +661% |
| Q2 2024 | $175.9K | +173% |
| Q1 2024 | $162.6K | +419% |
BRTX's revenue has slid since its 2023 peak: $34,586 last quarter, down 71% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q4 2025 | -11060% | -8799 points |
| Q3 2025 | -6424% | -5445 points |
| Q2 2025 | -1090% | +313 points |
| Q1 2025 | -4809% | -2282 points |
| Q4 2024 | -2261% | -1405 points |
| Q3 2024 | -979% | +9133 points |
| Q2 2024 | -1403% | +3429 points |
| Q1 2024 | -2527% | +15936 points |
BRTX's operating margin was −11060% last quarter, down 8799 points from the same quarter a year ago.
BRTX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | -$2.5M | -$134.6K |
| Q3 2025 | -$2.9M | -$1.1M |
| Q4 2024 | -$2.4M | -$516.8K |
| Q3 2024 | -$1.8M | -$568.3K |
| Q4 2023 | -$1.8M | -$227.5K |
| Q3 2023 | -$1.2M | +$237.4K |
| Q2 2023 | -$1.2M | +$229.4K |
| Q1 2023 | -$2.4M | -$704.6K |
BRTX has burned cash in almost every quarter: −$11M over the past year, against −$7M the year before.
BRTX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +94% | +431K shares |
| 1 year | +128% | +498K shares |
| 3 years | +387% | +704K shares |
| 5 years | +7286% | +874K shares |
BRTX has 886,387 diluted shares, up 128% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2026 | — |
BRTX Net Leverage
BRTX's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
BRTX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 28.8 | Oversold |
| Stochastic | 5.3 | Oversold |
BRTX's weekly RSI is 29 (oversold) and its Stochastic is 5 (oversold).
BRTX PE vs Healthcare Sector
BRTX has no meaningful PE right now: it lost money over the past year.
BRTX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1.77 | 15% below |
| 20 week MA | $3.54 | 58% below |
| 50 week MA | $8.25 | 82% below |
| 100 week MA | $20.7 | 93% below |
| 200 week MA | $33.5 | 96% below |
BRTX is in a downtrend: it's below all five of its weekly moving averages, and 96% below its 200-week average.
BRTX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $640.0 | $664.0 | +3.8% |
| 2021 | $664.0 | $96.0 | -86% |
| 2022 | $96.0 | $59.8 | -38% |
| 2023 | $59.8 | $34.8 | -42% |
| 2024 | $34.8 | $31.0 | -11% |
| 2025 | $31.0 | $22.4 | -28% |
| 2026 YTD | $22.4 | $1.50 | -93% |
BRTX has finished five years in a row lower, and it's down 93% so far in 2026.